Stock Events

Stock Events

Ligand Pharmaceuticals 

$0
39
-$0-3.85% Monday 19:45

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
60
Avg. Volume
-
Mkt Cap
39,882
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 18
$0.11
Jul 18
$0.11
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
1.19
1.82
2.46
3.09
Expected EPS
1.844286
Actual EPS
N/A

Financials

46.42%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
536.17MRevenue
248.91MNet Income

Analyst Ratings

$245.00Average Price Target
The highest estimate is 277.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGNXZ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor due to its focus on creating new drugs and therapies, similar to Ligand's business model of developing or acquiring technologies that help in drug discovery.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, focusing on antiviral drugs, which overlaps with Ligand's interest in drug development and licensing.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a direct competitor in the biotech industry, with a broad portfolio of treatments that could compete with Ligand's drug development platforms.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of pharmaceutical products, directly competing with Ligand's business model.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes with Ligand in the biopharmaceutical sector, especially in the areas of drug discovery and development.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation operates in the same space as Ligand, focusing on the discovery, development, and commercialization of proprietary therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical targets rare diseases with its genetic disorder treatments, competing with Ligand's focus on novel therapeutics.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk, while primarily known for diabetes care, also competes in the biopharmaceutical space, potentially overlapping with Ligand's therapeutic areas.

About

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
Show more...
CEO
Mr. Todd C. Davis Ph.D.
Employees
68
Country
US
ISIN
US53220K1815

Listings

OTC Link
US
LGNZZ
OTC Link
US
LGNXZ
XNAS
US
LGND
F
DE
LGDN.F

0 Comments

Share your thoughts

FAQ

What is Ligand Pharmaceuticals stock price today?▼
The current price of LGNXZ is $0 USD — it has decreased by -3.85% in the past 24 hours. Watch Ligand Pharmaceuticals stock price performance more closely on the chart.
What is Ligand Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ligand Pharmaceuticals stocks are traded under the ticker LGNXZ.
What is Ligand Pharmaceuticals market cap?▼
Today Ligand Pharmaceuticals has the market capitalization of 39,882
When is the next Ligand Pharmaceuticals earnings date?▼
Ligand Pharmaceuticals is going to release the next earnings report on May 06, 2026.
What were Ligand Pharmaceuticals earnings last quarter?▼
LGNXZ earnings for the last quarter are 2.02 USD per share, whereas the estimation was 1.5 USD resulting in a +34.92% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ligand Pharmaceuticals revenue for the last year?▼
Ligand Pharmaceuticals revenue for the last year amounts to 536.17M USD.
What is Ligand Pharmaceuticals net income for the last year?▼
LGNXZ net income for the last year is 248.91M USD.
Does Ligand Pharmaceuticals pay dividends?▼
Yes, LGNXZ dividends are paid en. The last dividend per share was 0.11 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Ligand Pharmaceuticals have?▼
As of March 19, 2026, the company has 68 employees.
When did Ligand Pharmaceuticals complete a stock split?▼
Ligand Pharmaceuticals has not had any recent stock splits.
Where is Ligand Pharmaceuticals headquartered?▼
Ligand Pharmaceuticals is headquartered in Jupiter, US.